Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Glucophage XR Gets 35% Of New Rxs From Metformin Switches

Executive Summary

Bristol-Myers Squibb's Glucophage XR extended-release metformin for type 2 diabetes is getting 35% of its new prescriptions from patients switching off the company's immediate-release Glucophage, Bristol President-Worldwide Medicines Group Richard Lane told a Jan. 24 conference call.

You may also be interested in...



MaxiPost-mortem

Second Phase III trial of stroke therapy MaxiPost "showed no significant difference in the overall efficacy and safety or tolerability between MaxiPost and placebo," Bristol reports. The first trial similarly failed to show evidence of benefit (1"The Pink Sheet" Jan. 29, p. 22). "We are now in the process of analyzing the data a little further, and we are going to review our options after that"

Bristol Repositions Glucovance, Glucophage XR As Metformin Generics Loom

A money-back guarantee will be part of Bristol-Myers Squibb's repositioning efforts for the metformin line extensions Glucophage XR and Glucovance.

MaxiPost-mortem

Second Phase III trial of stroke therapy MaxiPost "showed no significant difference in the overall efficacy and safety or tolerability between MaxiPost and placebo," Bristol reports. The first trial similarly failed to show evidence of benefit (1"The Pink Sheet" Jan. 29, p. 22). "We are now in the process of analyzing the data a little further, and we are going to review our options after that"

Related Content

UsernamePublicRestriction

Register

PS037239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel